Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesAdministrative/Operational PolicyBlue Cross Blue Shield OK Prior Auth Codes Update …
    Ask Trek AI about this page
    ModifiedBlue Cross Blue Shield - OklahomaPolicy N/A

    2025 Commercial Outpatient Specialty Pharmacy Prior Authorization Codes (Updated April 2025)

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - Oklahoma policy alerts

    Know when Blue Cross Blue Shield - Oklahoma releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governs procedure code-level prior authorization requirements for medical-benefit specialty pharmacy (provider-administered therapy and infusion site of care) for BCBSOK commercial members and delegates (Carelon) effective Jan 1, 2025; affects providers submitting PA requests.

    Policy Summary
    PayerBlue Cross Blue Shield - Oklahoma
    PolicyCommercial Outpatient Specialty Pharmacy Prior Authorization Codes (Jan 1, 2025; updated Apr 2025)
    Policy CodePolicy N/A
    Change TypeCode additions, delegation clarifications, effective/retirement dates
    Effective DateJan 1, 2025
    Next Review DateN/A
    Key ActionSend PA requests to BCBSOK for provider-administered therapy or infusion site of care; send PA requests to Carelon for oncology-supported medical oncology and supportive care.
    SourceLink
    POLICY UPDATE CHANGES

    Multiple HCPCS/CPT procedure codes and drug-to-code mappings were added with effective dates throughout 2024–2025 and some codes were added to Infusion Site of Care categories effective 07/01/2025.

    Carelon Medical Benefits Management will review medical oncology and supportive care prior authorization requests supported by an oncology diagnosis; BCBSOK reviews non-oncology indications and provider-administered or site-of-care reviews as delegated.

    Specific drugs (e.g., Tecentriq Hybreza, Unituxin, Avzivi, multiple biosimilars and new agents) were assigned to specific procedure codes with stated effective dates including future 07/01/2025 additions.

    Multiple J-, Q-, and C-codes were added to the Provider Administered Drug Therapy and Medical Oncology & Supportive Care categories effective 01/01/2025 (with some additions effective 04/01/2025).

    Carelon will review requests for oncology drugs that are supported by an oncology diagnosis; if not oncology-related, BCBS will review.

    Prior authorization required through BCBS or Carelon is specified for many listed codes.

    Code J0641 (Levoleucovorin NOS) was retired effective 01/01/2025.

    Codes C9169 and C9170 were slated to be added 01/01/2025 but were replaced with J9028 and J9026 respectively.

    Multiple J- and Q-codes and specific biologics/therapies were added with effective dates (for example, additions effective 01/01/2025 and 04/01/2025).

    Some HCPCS codes are marked for retirement (for example, J9258 and J9259 show 'Retire Effective' notes).

    Infusion site-of-care assignments were added on 04/01/24 and removed 10/01/24 for multiple codes.

    01/01/2025Primary effective date for many code additions
    Jan 1, 2025Baseline effective date for PA requirement
    07/01/2025Common add-to-Infusion-Site date
    MultipleNewly added/assigned codes (2024–2025)
    Prior AuthorizationPA requirement specified for many codes

    Coverage and Prior Authorization Criteria

    Prior authorization requirement and manager assignment

    Codes listed require benefit prior authorization for BCBSOK Fully Insured (FI) and ASO members; management of prior authorization may be delegated to Carelon for oncology-supported indications.

    Procedure codes on this list may require prior authorization for BCBSOK Fully Insured (FI) and Administrative Service Organization (ASO) members as of Jan 1, 2025 (see individual code entries for effective dates).
    Providers are generally responsible for requesting prior authorization prior to performing a service when the member is receiving in‑network care.
    Management assignment: send PA requests to BCBSOK for Provider Administered Therapy or Infusion Site of Care; send PA requests to Carelon for Medical Oncology & Supportive Care when the drug request is supported by an oncology diagnosis.
    Carelon will only review requests for oncology drugs that are supported by an oncology diagnosis; if the drug requested is not associated with an oncology diagnosis, BCBSOK will review the request.

    Coverage/authorization summary

    Many listed codes are assigned to one or more service categories and have per-code reviewer and prior authorization designations; refer to individual entries for examples and effective dates.

    Service category assignments used in the list include: Infusion Site of Care, Medical Oncology & Supportive Care, and Provider Administered Drug Therapy.
    Per-code reviewer designation: entries indicate whether managed by BCBSOK or Carelon (examples: J0129 and J0180 show 'Prior Authorization required through BCBS'; J1442, J1447, J1448, J1449, J2506, J2820 indicate 'Prior Authorization required through Carelon').

    See individual code rows for specific 'Managed By' and 'Prior Authorization required through ...' annotations.

    Effective dates: many additions to categories and PA requirements are effective 01/01/2025; some entries list other add/retire effective dates (for example Add Effective 04/01/2025 or Add to Infusion Site of Care 07/01/2025).

    Administrative coverage controls

    Administrative controls and operational flags present in the code listings include per-code prior authorization routing, add/retire effective dates, and site-of-care changes.

    Per-code prior authorization routing

    • Some J- and Q-codes are annotated 'Prior Authorization required through Carelon' (examples shown in Medical Oncology & Supportive Care rows).
    • Certain provider‑administered codes are annotated 'Prior Authorization required through BCBS' (examples include 90378, J0202, J0567 and others).
    Administrative timeline controls: multiple entries include 'Add Effective' or 'Retire Effective' dates which affect when a code requires PA or moves between categories.
    Infusion site-of-care status changes: several codes were 'Added to Infusion Site of Care' on earlier dates and later 'Removed from Infusion Site of Care' as noted in individual entries.
    Providers must check each code row for 'Managed By', 'Prior Authorization required through ...', and 'Add/Retire Effective' notes to determine current PA routing and site-of-care assignments.

    Operational implication

    Coverage stance and operational criteria (excerpt)

    High-level coverage and operational guidance for providers when using this list:

    Presence of a code on this list does not guarantee coverage under a member's benefit contract; verify eligibility and benefits before requesting authorization via Availity or the preferred vendor portal.
    Prior authorization is required for some members/services/drugs before services are rendered to confirm medical necessity as defined by the member's health benefit plan; once processed, the decision will be communicated to the provider.
    Routing and vendor rules: for some services or members, prior authorization may be required through other BCBS entities or through Carelon Medical Benefits Management per BCBSOK contract—check the per-code 'Managed By' field.
    If you have questions about prior authorization requirements or routing, contact the prior authorization phone number on the member's ID card or use your portal vendor.

    Code Listings and Status

    Immune globulin injectionsHCPCSCovered
    J1552Injection, immune globulin (alyglo), 500 mg
    J1576Injection Immune Globulin (Panzyga) Intravenous Non-Lyophilized 500 mg
    Selected Q-codes (cell and biosimilar therapies)HCPCSCovered
    Q2057Afamitresgene autoleucel, including leukapheresis and dose preparation, per therapeutic dose
    Q5133Injection, Tocilizumab-Bavi (Tofidence), Biosimilar, 1 mg
    Antineoplastic / oncology unclassified codesHCPCSCovered
    J9161Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) / maps to Lymphir in table
    J9999Not Otherwise Classified Antineoplastic Drugs (includes Tecentriq Hybreza entry)
    Infliximab biosimilarsmixedCovered
    Q5103Infliximab-Dyyb (Inflectra) 10 mg
    Q5104Infliximab-Abda (Renflexis) 10 mg
    Q5109Infliximab-Qbtx (Ixifi) 10 mg
    Q5121Infliximab-Axxq (Avsola) 10 mg
    Replaced C-codesmixed
    J9026tarlatamab-dlle, 1 mg (added effective 01/01/2025)
    J9028nogapendekin alfa inbakicept-pmln, intravesical 1 mcg (added effective 01/01/2025)
    Selected provider-administered drug HCPCS/J/Q codes in excerptmixed
    J9176Listed with Carelon; prior auth required
    J9258Paclitaxel protein-bound (Teva) – note: 'Retire Effective' appears
    J9264Paclitaxel protein-bound – prior auth required through Carelon
    Q2043Sipuleucel-T; prior auth required through Carelon
    90378Respiratory syncytial virus monoclonal antibody; prior auth required through BCBS
    Provider-administered J/Q code group (excerpt)HCPCS
    J1413Delandistrogene Moxeparvovec-Rokl / per therapeutic dose (provider-administered drug therapy)
    J1426Casimersen, 10 mg (provider-administered drug therapy)
    J1427Viltolarsen, 10 mg (provider-administered drug therapy)
    J1428Eteplirsen, 10 mg (provider-administered drug therapy)
    J1429Golodirsen, 10 mg (provider-administered drug therapy)
    J1628Guselkumab, 1 mg (provider-administered drug therapy)
    J1747Spesolimab-Sbzo, 1 mg (provider-administered drug therapy)
    J1961Lenacapavir, 1 mg (provider-administered drug therapy)
    J2267Mirikizumab-mrkz (provider-administered drug therapy)
    J2326Nusinersen, 0.1 mg (provider-administered drug therapy)
    1–10 of 31
    1/4
    Document searchability
    Searchable formatDocument is a searchable PDF; providers should use Ctrl+F to find procedure codes and related entries.
    PurposeList includes procedure code changes for Medical Benefit Specialty Pharmacy that may require benefit prior authorization effective Jan 1, 2025 for BCBSOK FI & ASO members.
    Use guidanceUse the document to view drug product name, reason for prior authorization (therapy and/or infusion site), and effective dates for implementation.
    Additions effective 04/01/2025
    Effective additions on 04/01/2025Select codes (example: J2802) are noted with 'Add Effective 04/01/2025' in the list.
    Other 2025 effective datesMany additions are effective 01/01/2025; some entries show 'Add Effective 01/01/2025' or retirement dates in 2025.
    Verify per-entry datesCheck each code line for its specific 'Add Effective' or 'Retire Effective' notes; dates vary by code.

    Provider Submission, Routing, and Authorization Actions

    Prior Authorization

    Route PA requests to BCBSOK or Carelon based on therapy and indication

    Send PA requests to BCBSOK for Provider Administered Therapy or Infusion Site of Care. Send PA requests to Carelon for Medical Oncology and Supportive Care unless the drug requested has multiple indications; Carelon will only review requests for oncology drugs that are supported by an oncology diagnosis.

    • If drug is not associated with an oncology diagnosis, BCBSOK will review the request.
    • Refer to the Update History / Prior Authorization Delegation Notes for details on specific code routing.
    Prior Authorization

    Carelon reviews oncology-supported drug requests only

    Carelon will only review requests for oncology drugs when the request is supported by an oncology diagnosis; requests for non-oncology indications will be reviewed by BCBSOK.

    • If a drug has multiple indications, follow the delegation notes to determine whether Carelon or BCBSOK manages the review.
    • Delegation applies to Medical Oncology & Supportive Care categories assigned to Carelon in the code listing.
    Prior Authorization

    Submit PA requests to BCBSOK for specified J-codes

    Prior Authorization is required through BCBSOK for many listed J-codes (example entries show J0129 and J0180 marked 'Prior Authorization required through BCBS').

    • Examples in the list: J0129 = Prior Authorization required through BCBS; J0180 = Prior Authorization required through BCBS.
    • Check the per-code entry to confirm BCBSOK as the managing entity and any effective dates.
    Prior Authorization

    Submit PA requests to Carelon for Medical Oncology & Supportive Care codes

    Prior Authorization is required through Carelon for many Medical Oncology & Supportive Care J-/Q-/J9xxx codes (per-code entries indicate 'Prior Authorization required through Carelon').

    • Examples in the list: J1442, J1447, J1448, J1449, J2506 and other Medical Oncology & Supportive Care codes show prior authorization through Carelon.
    • Confirm per-code Carelon assignment and any add/effective dates in the code listing.
    Documentation Required

    Reviewer assignment depends on oncology diagnosis

    Carelon will review oncology drug requests when supported by an oncology diagnosis; BCBSOK will review requests not associated with an oncology diagnosis.

    • This reviewer assignment is repeated across multiple code entries that list 'Carelon or BCBSOK' and include the note about oncology diagnosis support.
    • When in doubt, consult the code-level 'Managed By' field to determine the reviewer.
    Prior Authorization

    Per-code PA submissions routed to Carelon where indicated

    Many listed J-codes are annotated 'Prior Authorization required through Carelon' in the code listing (examples include J9176, J9177, J9179, J9203).

    • Confirm Carelon assignment and prior authorization requirement on the per-code line before submitting.
    • Follow Carelon processes for prior authorization submission when the per-code entry indicates Carelon.
    Prior Authorization

    Per-code PA submissions routed to BCBSOK where indicated

    Several provider-administered codes are annotated 'Prior Authorization required through BCBS' and list BCBSOK as the managing entity (examples: 90378, J0202, J0567, J1413, J1426–J1429, J2326).

    • Verify the per-code 'BCBSOK' assignment in the listing and submit PA requests to BCBSOK for those codes.
    • Note add/retire effective dates on per-code lines when present.
    Prior Authorization

    Provider responsibility: request PA before service when required

    Prior authorization is required for some members/services/drugs before services are rendered to confirm medical necessity; usually the provider is responsible for requesting prior authorization before performing a service for in-network care.

    • Once a prior authorization request is received and processed, the decision is communicated to the provider.
    • If you have questions, call the prior authorization number on the member's ID card; always verify eligibility and benefits via Availity or your preferred portal.
    Note

    Check per-code PA flags to determine submission routing

    Multiple HCPCS J-/Q-/J-like codes in the listing include per-code annotations indicating which entity manages prior authorization (for example, entries marked 'Prior Authorization required through BCBS' or 'Prior Authorization required through Carelon').

    • Review each code line for the 'Managed By' and 'Prior Authorization' notes to determine where to submit the request.
    • Some codes are listed as 'Carelon or BCBSOK' — check the associated diagnosis and delegation notes to route the PA.
    Documentation Required

    External vendor assignments: Carelon and other BCBS entities may manage PA

    For some services/members, prior authorization may be required through other BCBS entities or through Carelon Medical Benefits Management per BCBSOK contract; Availity or the member's ID card should be used to confirm vendor and prior authorization number.

    • BCBSOK has contracted with Carelon for utilization management and related services for some members; other Blue plans may also require separate PA processes.
    • Always verify which vendor to use for prior authorization on a per-member basis via Availity or the member ID card.

    Terms and Vendor Definitions

    Carelon
    DefinitionCarelon Medical Benefits Management = Med Oncology & Supportive Care.
    Delegation roleCarelon will review prior authorization requests for oncology drugs when supported by an oncology diagnosis.
    When BCBSOK reviewsIf the drug requested is not associated with an oncology diagnosis, the request will be reviewed by BCBSOK.
    PA routing
    Routing ruleSend PA requests to BCBSOK for Provider Administered Therapy or Infusion Site of Care; send to Carelon for Medical Oncology & Supportive Care when oncology diagnosis supports the request.
    Multiple indicationsIf a drug has multiple indications, delegation may vary; refer to Update History / Prior Authorization Delegation Notes.
    Provider responsibilityProviders should follow the specified routing per code to ensure the correct reviewer receives the PA request.
    Carelon
    Carelon assignmentMany Medical Oncology & Supportive Care entries list 'Carelon' as the managing reviewer (Carelon or BCBSOK stated where applicable).
    Carelon review criterionCarelon will only review oncology drug requests supported by an oncology diagnosis.
    Add/assignment datesEntries show additions to Provider Administered Therapy or Medical Oncology categories with effective dates (for example, Add to Provider Administered Drug Therapy 01/01/25).
    BCBSOK
    OrganizationBCBSOK = Provider Administered Therapy or Infusion Site of Care reviewer.
    BCBSOK PA responsibilityBCBSOK reviews requests that are not oncology-supported and handles Provider Administered Drug Therapy and Infusion Site of Care prior authorizations as listed per code.
    Infusion site notesSeveral codes are marked 'Added to Infusion Site of Care' or 'Removed from Infusion Site of Care' with dates; BCBSOK-listed codes may include these site assignments.
    Prior Authorization routing
    Primary routing rulePer-code entries specify whether prior authorization requests are to be routed to Carelon or BCBSOK; follow the per-code 'Managed By' or reviewer field.
    Examples routed to CarelonSeveral oncology J-codes (e.g., J9176, J9177, J9179, J9203) are annotated 'Carelon' and 'Prior Authorization required through Carelon'.
    Examples routed to BCBSOKMultiple provider-administered codes (e.g., J0202, J0567, J2507) are annotated 'BCBSOK' with 'Prior Authorization required through BCBS'.
    Infusion Site of Care status
    Infusion site status changesMany codes show 'Added to Infusion Site of Care 04/01/24' and 'Removed from Infusion Site of Care 10/01/24' in their entries.
    Future additions to Infusion Site of CareSome codes are noted to be 'Add to Infusion Site of Care' effective 07/01/2025 (per specific code entries like J1552 and J1576).
    Verify per-code historyCheck each code's line for exact 'Added' and 'Removed' dates as they differ by code.
    Prior authorization
    Prior authorization requirementPrior authorization is required for some members/services/drugs before services are rendered to confirm medical necessity as defined by the member's health benefit plan.
    Provider actionUsually, the provider is responsible for requesting prior authorization before performing a service if the member is seeing an in-network provider.
    Confirmation & questionsOnce a PA request is received and processed, the decision is communicated to the provider; contact the PA number on the member's ID card with questions.
    Third-party vendors
    Availity / portalsAlways check eligibility and benefits first through Availity Essentials or your preferred web vendor portal to confirm coverage and prior authorization requirements.
    Third-party utilization managementBCBSOK has contracted with Carelon Medical Benefits Management for utilization management services for some members; some PAs may be required through other BCBS entities per contract.
    Vendor examplesAvaility used for eligibility/benefits checking; Carelon used for oncology utilization management where contracted.
    Policy Summary
    PayerBlue Cross Blue Shield - Oklahoma
    PolicyCommercial Outpatient Specialty Pharmacy Prior Authorization Codes (Jan 1, 2025; updated Apr 2025)
    Policy CodePolicy N/A
    Change TypeCode additions, delegation clarifications, effective/retirement dates
    Effective DateJan 1, 2025
    Next Review DateN/A
    Key ActionSend PA requests to BCBSOK for provider-administered therapy or infusion site of care; send PA requests to Carelon for oncology-supported medical oncology and supportive care.
    SourceLink
    On This Page
    Coverage and Prior Authorization CriteriaCode Listings and StatusProvider Submission, Routing, and Authorization ActionsTerms and Vendor Definitions

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.